LKFT — Lakefront Biotherapeutics NV Share News
0.000.00%
Last trade - 00:00- €1.77bn
- -€467.06m
- €1.11bn
RBC upgrades Lakefront Biotherapeutics to 'outperform' on gamgertamig prospect
Brief: U.S. FDA Grants Orphan Drug Designation To Gamgertamig For The Treatment Of Pemphigus
Brief: Lakefront Biotherapeutics H1 Net Profit From Continuing Operations €15.8 Mln
Brief: Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
Brief: Lakefront Receives Transparency Notification From Bank Of America
Belgium's Galapagos Q1 revenue falls 91% but returns to profit
Brief: Galapagos, Gilead Enter Binding Agreement On Ouro Medicines Acquisition
Brief: Galapagos Announces Nomination Of Gino Santini To Its Board Of Directors
Brief: Gilead Sciences To Buy Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases
Brief: Galapagos NV - Creates 1,750,000 Subscription Rights Under New Subscription Right Plan
Belgium's Galapagos 2025 net revenue surges, driven by Gilead collaboration
Brief: Galapagos FY Net Income EUR 320.9 Million
Brief: Galapagos Announces Board Decision To Initiate Wind-Down Of Cell Therapy Activities
Brief: Galapagos Presented New Atalanta-1 Cell Therapy Data In MCL
Brief: Galapagos 9M Revenue EUR 211.4 Million
Galapagos shares heading for their worst day in almost 5 years after CAR T business wind-down announcement
Biotech firm Galapagos to wind down cell therapy business
Brief: Galapagos To Wind Down Its Cell Therapy Business
Biotechnology firm Galapagos receives offers for cell therapy business (updated)